These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 1979466)

  • 21. Different immunophenotype and autoantibody production by peripheral blood and thyroid-derived lymphocytes in patients with Graves' disease.
    Aust G; Lehmann I; Heberling HJ
    Exp Clin Endocrinol Diabetes; 1996; 104(1):50-8. PubMed ID: 8750571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum immunoglobulin G4 levels and Graves' disease phenotype.
    Martin CS; Sirbu AE; Betivoiu MA; Florea S; Barbu CG; Fica SV
    Endocrine; 2017 Feb; 55(2):478-484. PubMed ID: 27819113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced thyroid iodine metabolism in patients with triiodothyronine-predominant Graves' disease.
    Takamatsu J; Hosoya T; Naito N; Yoshimura H; Kohno Y; Tarutani O; Kuma K; Sakane S; Takeda K; Mozai T
    J Clin Endocrinol Metab; 1988 Jan; 66(1):147-52. PubMed ID: 3335601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impaired intrathyroidal iodine organification and iodine-induced hypothyroidism in euthyroid women with a previous episode of postpartum thyroiditis.
    Roti E; Minelli R; Gardini E; Bianconi L; Neri T; Gavaruzzi G; Ugolotti G; Salvo D; Braverman LE
    J Clin Endocrinol Metab; 1991 Nov; 73(5):958-63. PubMed ID: 1658032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of remission after antithyroid drug treatment in Graves' disease.
    Young ET; Steel NR; Taylor JJ; Stephenson AM; Stratton A; Holcombe M; Kendall-Taylor P
    Q J Med; 1988 Feb; 66(250):175-89. PubMed ID: 2902655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis.
    Sato A; Yamada T; Aizawa T; Ichikawa K; Komiya I; Takasu N; Takemura Y
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thyroid function parameters and TSH-receptor antibodies in healthy subjects and Graves' disease patients: a sequential study before, during and after pregnancy.
    González-Jiménez A; Fernández-Soto ML; Escobar-Jiménez F; Glinoer D; Navarrete L
    Thyroidology; 1993 Apr; 5(1):13-20. PubMed ID: 7508738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abnormal B lymphocyte function in thyroid glands from patients with Graves' disease.
    Ueki Y; Eguchi K; Otsubo T; Kawabe Y; Shimomura C; Tezuka H; Nakao H; Kawakami A; Migita K; Ishikawa
    J Clin Endocrinol Metab; 1989 Nov; 69(5):939-45. PubMed ID: 2793996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative study on IgG and IgA antibodies against human thyroid and eye-muscle antigens in Graves' ophthalmopathy.
    Molnár I; Balázs C
    Acta Med Hung; 1991; 48(1-2):13-21. PubMed ID: 1813853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease.
    Nakazato N; Yoshida K; Mori K; Kiso Y; Sayama N; Tani JI; Nakagawa Y; Ito S
    Thyroid; 1999 Aug; 9(8):775-9. PubMed ID: 10482369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thyrotropin receptor antibodies in hypothyroid Graves' disease.
    Kasagi K; Hidaka A; Nakamura H; Takeuchi R; Misaki T; Iida Y; Konishi J
    J Clin Endocrinol Metab; 1993 Feb; 76(2):504-8. PubMed ID: 8094394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of thyroid stimulating antibodies and TSH-binding inhibiting immunoglobulins in the follow-up of Graves' disease.
    Hörmann R; Saller B; Müller R; Mann K
    Klin Wochenschr; 1985 Dec; 63(24):1247-52. PubMed ID: 2868149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Graves' IgG stimulation of iodide uptake in FRTL-5 rat thyroid cells: a clinical assay complementing FRTL-5 assays measuring adenylate cyclase and growth-stimulating antibodies in autoimmune thyroid disease.
    Marcocci C; Valente WA; Pinchera A; Aloj SM; Kohn LD; Grollman EF
    J Endocrinol Invest; 1983 Dec; 6(6):463-71. PubMed ID: 6689493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pretreatment with betamethasone of patients with Graves' disease given radioiodine therapy: thyroid autoantibody responses and outcome of therapy.
    Gamstedt A; Karlsson A
    J Clin Endocrinol Metab; 1991 Jul; 73(1):125-31. PubMed ID: 2045463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum thyroid-stimulating antibody, thyroglobulin levels, and thyroid suppressibility measurement as predictors of the outcome of combined methimazole and triiodothyronine therapy in Graves' disease.
    Werner RS; Romaldini JH; Farah CS; Werner MC; Bromberg N
    Thyroid; 1991; 1(4):293-9. PubMed ID: 1688155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Graves' immunoglobulin G stimulates iodide efflux in FRTL-5 thyroid cells.
    Shoda Y; Kondo Y; Kobayashi I
    J Clin Endocrinol Metab; 1993 Jul; 77(1):94-7. PubMed ID: 8100833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The presence of higher levels of thyroglobulin, but not thyroid autoantibodies, in the thyroid vein in Graves' disease.
    Chou FF; Wang PW; Sheen-Chen SM
    J Endocrinol Invest; 1994 Jan; 17(1):41-4. PubMed ID: 7911812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of outcome in Graves' disease after carbimazole treatment.
    Weetman AP; Ratanachaiyavong S; Middleton GW; Love W; John R; Owen GM; Darke C; Lazarus JH; Hall R; McGregor AM
    Q J Med; 1986 Apr; 59(228):409-19. PubMed ID: 2875484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.